$21.00
-0.08 (-0.38%)
Open$21.31
Previous Close$21.08
Day High$21.78
Day Low$20.60
52W High$29.28
52W Low$5.77
Volume—
Avg Volume244.5K
Market Cap696.03M
P/E Ratio—
EPS$-1.89
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+30.5% upside
Current
$21.00
$21.00
Target
$27.40
$27.40
$23.46
$27.40 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 66.09M | 69.56M | 73.83M |
| Net Income | 7.65M | 9.76M | 11.38M |
| Profit Margin | 11.6% | 14.0% | 15.4% |
| EBITDA | 12.79M | 14.57M | 15.15M |
| Free Cash Flow | 6.98M | 8.54M | 10.02M |
| Rev Growth | +12.3% | +24.1% | -0.1% |
| Debt/Equity | 0.76 | 0.65 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |